Sveva holds a Bachelor of Science in Biotechnology from the University of Siena and a Master in Biomedical Sciences from King’s College London. She started her PhD in April 2021 focusing on a project founded by the HORIZON2020 scheme. Her project aims at obtaining a 3D in vitro model to recapitulate the native kidney structure and functions for disease modelling and drug testing.
Chronic Kidney Disease (CKD) is a major public challenge characterized by a progressive decrease in renal functions associated with poor survival and end-stage organ complications. At present, dialysis and transplantation are the only therapeutic options for these patients.
Different nephrotoxicants –among which drugs- can damage the tubular system of the nephron, but still the molecular mechanisms leading to CKD are poorly understood.
Therefore, in her PhD, she will develop a humanized 3D bioprinted on-chip model to explore the mechanisms of CKD and provide a more reliable drug screening platform.